Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Biomarker

PUBLISHER: Grand View Research | PRODUCT CODE: 1611513

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1611513

Biomarker Testing Services Market Size, Share & Trends Analysis Report By Service, By Application, By Type, By End-use,By Region, And Segment Forecasts, 2025 - 2030

PUBLISHED:
PAGES: 150 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 5950
Printable PDF (5-User License)
USD 6950
Printable PDF (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

List of Tables

Biomarker Testing Services Market Growth & Trends:

The global biomarker testing services market size is expected to reach USD 1.06 billion by 2030, registering a CAGR of 8.59% from 2025 to 2030, according to a new report by Grand View Research, Inc. Growing investment in pharmaceutical R&D, increasing demand for the precision medicine used for cancer treatment, and growing burden of the infectious and chronic diseases facilitating the demand for the biomarker testing are some of the major factors driving the market's growth.

There has been a consistent rise in clinical trials during the last 5 years. For instance, according to ClinicalTrials.gov, more than 262,298 trials were registered in 2018, whereas as of September 2022, above 399,518 trials were registered. Clinical trials are expected to improve in the coming years owing to the increase in funding for clinical research. This is expected to boost demand for medicine discovery research activities and thus support demand for biomarker testing in the post-pandemic period.

The FDA approval rate for medicines through the use of biomarkers has improved, over the years. For instance, in 2016, more than 26 trials were approved by the FDA that used biomarkers for medicine testing, whereas, in 2019, 36 trials were approved by the FDA that used biomarkers for medical testing. Clinical trials now require biomarker-related data for medicine approvals, as it provides information about the action of medicine in the body and thus speeds up the medicine approval process. This is expected to improve demand for biomarker testing during the forecast period.

Various biopharmaceutical companies are taking initiatives to improve the diagnosis rate of the cancer patient through biomarker testing. For instance, in April 2021, a biopharmaceutical company, Amgen launched the Biomarker Assist Program. As per this program, patients with metastatic (stage IV) non-small cell lung cancer (NSCLC) were provided biomarker testing, to check the presence of oncogene biomarkers, which help in targeted therapies. Such initiatives by the market players are likely to support the market's growth.

According to the IQVIA, report on oncology trends, clinical trials for cancer have been increasing for the last 10 years. For instance, in 2011, 1,242 trials were registered for cancer, and as of 2021, 2,335 trials were registered for cancer. The number of clinical trials intended for cancer is expected to rise even further owing to the growing prevalence of the disease. There is an increasing demand for targeted therapies designed for cancer that use biomarkers for testing the efficacy of the drug in the research. Increased cancer research in the coming years is expected to boost demand for the biomarkers designed for cancer testing and thus support the market in the post-pandemic period.

Biomarker Testing Services Market Report Highlights:

  • The biomarker assay development & validation segment by service was expected to hold the largest share of 45.77% in 2024. Growing demand for companion diagnostics in the diagnosis of diseases is expected to support demand for the biomarker assay development & validation service
  • Based on end-user, the pharmaceutical and biotechnology companies accounted for the largest share of 45.45% in 2024, owing to the rising investment in R&D by these companies
  • North America held the largest share of 46.23% in 2024, The technologically advanced infrastructure for research and the increase in research investment by public organizations are supporting the regional market growth
Show more
Product Code: GVR-4-68039-986-1

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
    • 1.2.1. Service Segment
    • 1.2.2. Application Segment
    • 1.2.3. Type Segment
    • 1.2.4. End Use Segment
  • 1.3. Information Analysis
    • 1.3.1. Market Formulation & Data Visualization
  • 1.4. Data Validation & Publishing
  • 1.5. Information Procurement
    • 1.5.1. Primary Research
  • 1.6. Information or Data Analysis
  • 1.7. Market Formulation & Validation
  • 1.8. Market Model
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Biomarker Testing Services Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing Demand for Biomarker Testing for Cancer Detection
      • 3.2.1.2. Increasing R&D Activities
      • 3.2.1.3. Growing Burden of Chronic and Infectious Diseases Supporting Demand for Biomarker Testing
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High Capital Investments and Lengthy Timelines for Biomarker Development
  • 3.3. Biomarker Testing Services Market: Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Biomarker Testing Services Market: Service Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Biomarker Testing Service Market Movement Analysis
  • 4.3. Global Biomarker Testing Service Market Size & Trend Analysis, by services, 2018 to 2030 (USD Million)
  • 4.4. Biomarker Assay Development & Validation
    • 4.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 4.5. Flow Cytometry
    • 4.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 4.6. Others
    • 4.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 5. Biomarker Testing Services Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Biomarker Testing Application Market Movement Analysis
  • 5.3. Global Biomarker Testing Service Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 5.4. Oncology
    • 5.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 5.5. Drug Discovery & Development
    • 5.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 5.6. Others
    • 5.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 6. Biomarker Testing Services Market: Type Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Biomarker Testing Services Market Movement Analysis
  • 6.3. Global Biomarker Testing Services Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 6.4. Molecular Biomarkers
    • 6.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 6.5. Cellular Biomarkers
    • 6.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 7. Biomarker Testing Services Market: End Use Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Global Biomarker Testing Services Market Movement Analysis
  • 7.3. Global Biomarker Testing Services Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 7.4. Pharmaceutical and Biotechnology Companies
    • 7.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 7.5. Research Institutes
    • 7.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 7.6. CROs
    • 7.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 8. Biomarker Testing Services Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Dashboard
  • 8.2. Global Regional Market Snapshot
  • 8.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 8.4. North America
    • 8.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Competitive Scenario
      • 8.4.2.3. Regulatory Scenario
      • 8.4.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Competitive Scenario
      • 8.4.3.3. Regulatory Scenario
      • 8.4.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Competitive Scenario
      • 8.4.4.3. Regulatory Scenario
      • 8.4.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.5. Europe
    • 8.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Competitive Scenario
      • 8.5.2.3. Regulatory Scenario
      • 8.5.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Competitive Scenario
      • 8.5.3.3. Regulatory Scenario
      • 8.5.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Competitive Scenario
      • 8.5.4.3. Regulatory Scenario
      • 8.5.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Competitive Scenario
      • 8.5.5.3. Regulatory Scenario
      • 8.5.5.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Competitive Scenario
      • 8.5.6.3. Regulatory Scenario
      • 8.5.6.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.5.7. Denmark
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Competitive Scenario
      • 8.5.7.3. Regulatory Scenario
      • 8.5.7.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.5.8. Sweden
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Competitive Scenario
      • 8.5.8.3. Regulatory Scenario
      • 8.5.8.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.5.9. Norway
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Competitive Scenario
      • 8.5.9.3. Regulatory Scenario
      • 8.5.9.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.6.2. China
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Competitive Scenario
      • 8.6.2.3. Regulatory Scenario
      • 8.6.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.6.3. Japan
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Competitive Scenario
      • 8.6.3.3. Regulatory Scenario
      • 8.6.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Competitive Scenario
      • 8.6.4.3. Regulatory Scenario
      • 8.6.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.6.5. Australia
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Competitive Scenario
      • 8.6.5.3. Regulatory Scenario
      • 8.6.5.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.6.6. South Korea
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Competitive Scenario
      • 8.6.6.3. Regulatory Scenario
      • 8.6.6.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.6.7. Thailand
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Competitive Scenario
      • 8.6.7.3. Regulatory Scenario
      • 8.6.7.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.6.8. Indonesia
      • 8.6.8.1. Key Country Dynamics
      • 8.6.8.2. Competitive Scenario
      • 8.6.8.3. Regulatory Scenario
      • 8.6.8.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.6.9. Malaysia
      • 8.6.9.1. Key Country Dynamics
      • 8.6.9.2. Competitive Scenario
      • 8.6.9.3. Regulatory Scenario
      • 8.6.9.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.6.10. Singapore
      • 8.6.10.1. Key Country Dynamics
      • 8.6.10.2. Competitive Scenario
      • 8.6.10.3. Regulatory Scenario
      • 8.6.10.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.6.11. Taiwan
      • 8.6.11.1. Key Country Dynamics
      • 8.6.11.2. Competitive Scenario
      • 8.6.11.3. Regulatory Scenario
      • 8.6.11.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Competitive Scenario
      • 8.7.2.3. Regulatory Scenario
      • 8.7.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Competitive Scenario
      • 8.7.3.3. Regulatory Scenario
      • 8.7.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.7.4. Colombia
      • 8.7.4.1. Key Country Dynamics
      • 8.7.4.2. Competitive Scenario
      • 8.7.4.3. Regulatory Scenario
      • 8.7.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.8. MEA
    • 8.8.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Competitive Scenario
      • 8.8.2.3. Regulatory Scenario
      • 8.8.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Competitive Scenario
      • 8.8.3.3. Regulatory Scenario
      • 8.8.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Competitive Scenario
      • 8.8.4.3. Regulatory Scenario
      • 8.8.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Competitive Scenario
      • 8.8.5.3. Regulatory Scenario
      • 8.8.5.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.8.6. Israel
      • 8.8.6.1. Key Country Dynamics
      • 8.8.6.2. Competitive Scenario
      • 8.8.6.3. Regulatory Scenario
      • 8.8.6.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Participant Categorization
  • 9.2. Strategy Mapping
  • 9.3. Company Market Position Analysis, 2024
  • 9.4. Company Profiles
    • 9.4.1. Bio Agilytix Labs
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Financial Performance
      • 9.4.1.3. Service Benchmarking
      • 9.4.1.4. Strategic Initiatives
    • 9.4.2. Eurofins Scientific
      • 9.4.2.1. Company Overview
      • 9.4.2.2. Financial Performance
      • 9.4.2.3. Service Benchmarking
      • 9.4.2.4. Strategic Initiatives
    • 9.4.3. SGS SA.
      • 9.4.3.1. Company Overview
      • 9.4.3.2. Financial Performance
      • 9.4.3.3. Service Benchmarking
      • 9.4.3.4. Strategic Initiatives
    • 9.4.4. Charles River Laboratories
      • 9.4.4.1. Company Overview
      • 9.4.4.2. Financial Performance
      • 9.4.4.3. Service Benchmarking
      • 9.4.4.4. Strategic Initiatives
    • 9.4.5. LabCorp
      • 9.4.5.1. Company Overview
      • 9.4.5.2. Financial Performance
      • 9.4.5.3. Service Benchmarking
      • 9.4.5.4. Strategic Initiatives
    • 9.4.6. Thermo Fisher Scientific Inc. (PPD, Inc.)
      • 9.4.6.1. Company Overview
      • 9.4.6.2. Financial Performance
      • 9.4.6.3. Service Benchmarking
      • 9.4.6.4. Strategic Initiatives
    • 9.4.7. ICON Plc
      • 9.4.7.1. Company Overview
      • 9.4.7.2. Financial Performance
      • 9.4.7.3. Service Benchmarking
      • 9.4.7.4. Strategic Initiatives
    • 9.4.8. IQVIA
      • 9.4.8.1. Company Overview
      • 9.4.8.2. Financial Performance
      • 9.4.8.3. Service Benchmarking
      • 9.4.8.4. Strategic Initiatives
    • 9.4.9. Syneos Health
      • 9.4.9.1. Company Overview
      • 9.4.9.2. Financial Performance
      • 9.4.9.3. Service Benchmarking
      • 9.4.9.4. Strategic Initiatives
    • 9.4.10. Intertek Group Plc
      • 9.4.10.1. Company Overview
      • 9.4.10.2. Financial Performance
      • 9.4.10.3. Service Benchmarking
      • 9.4.10.4. Strategic Initiatives
Show more
Product Code: GVR-4-68039-986-1

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 4 Global Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
  • Table 5 Global Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 6 Global Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 7 Global Biomarker Testing Services, by Region, 2018 - 2030 (USD Million)
  • Table 8 North America Biomarker Testing Services, by Country, 2018 - 2030 (USD Million)
  • Table 9 North America Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 10 North America Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
  • Table 11 North America Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 12 North America Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 13 U.S. Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 14 U.S. Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
  • Table 15 U.S. Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 16 U.S. Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 17 Canada Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 18 Canada Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
  • Table 19 Canada Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 20 Canada Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 21 Mexico Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 22 Mexico Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
  • Table 23 Mexico Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 24 Mexico Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 25 Europe Biomarker Testing Services, by Country, 2018 - 2030 (USD Million)
  • Table 26 Europe Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 27 Europe Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
  • Table 28 Europe Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 29 Europe Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 30 Germany Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 31 Germany Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
  • Table 32 Germany Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 33 Germany Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 34 UK Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 35 UK Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
  • Table 36 UK Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 37 UK Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 38 France Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 39 France Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
  • Table 40 France Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 41 France Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 42 Italy Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 43 Italy Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
  • Table 44 Italy Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 45 Italy Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 46 Spain Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 47 Spain Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
  • Table 48 Spain Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 49 Spain Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 50 Denmark Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 51 Denmark Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
  • Table 52 Denmark Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 53 Denmark Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 54 Sweden Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 55 Sweden Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
  • Table 56 Sweden Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 57 Sweden Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 58 Norway Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 59 Norway Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
  • Table 60 Norway Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 61 Norway Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 62 Asia Pacific Biomarker Testing Services, by Country, 2018 - 2030 (USD Million)
  • Table 63 Asia Pacific Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 64 Asia Pacific Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
  • Table 65 Asia Pacific Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 66 Asia Pacific Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 67 China Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 68 China Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
  • Table 69 China Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 70 China Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 71 Japan Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 72 Japan Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
  • Table 73 Japan Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 74 Japan Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 75 India Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 76 India Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
  • Table 77 India Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 78 India Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 79 South Korea Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 80 South Korea Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
  • Table 81 South Korea Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 82 South Korea Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 83 Australia Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 84 Australia Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
  • Table 85 Australia Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 86 Australia Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 87 Thailand Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 88 Thailand Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
  • Table 89 Thailand Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 90 Thailand Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 91 Indonesia Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 92 Indonesia Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
  • Table 93 Indonesia Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 94 Indonesia Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 95 Malaysia Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 96 Malaysia Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
  • Table 97 Malaysia Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 98 Malaysia Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 99 Singapore Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 100 Singapore Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
  • Table 101 Singapore Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 102 Singapore Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 103 Taiwan Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 104 Taiwan Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
  • Table 105 Taiwan Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 106 Taiwan Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 107 Latin America Biomarker Testing Services, by Country, 2018 - 2030 (USD Million)
  • Table 108 Latin America Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 109 Latin America Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
  • Table 110 Latin America Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 111 Latin America Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 112 Brazil Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 113 Brazil Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
  • Table 114 Brazil Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 115 Brazil Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 116 Argentina Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 117 Argentina Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
  • Table 118 Argentina Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 119 Argentina Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 120 Middle East & Africa Biomarker Testing Services, by Country, 2018 - 2030 (USD Million)
  • Table 121 Middle East & Africa Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 122 Middle East & Africa Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
  • Table 123 Middle East & Africa Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 124 Middle East & Africa Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 125 South Africa Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 126 South Africa Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
  • Table 127 South Africa Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 128 South Africa Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 129 Saudi Arabia Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 130 Saudi Arabia Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
  • Table 131 Saudi Arabia Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 132 Saudi Arabia Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 133 UAE Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 134 UAE Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
  • Table 135 UAE Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 136 UAE Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 137 Kuwait Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 138 Kuwait Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
  • Table 139 Kuwait Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 140 Kuwait Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 141 Israel Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 142 Israel Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
  • Table 143 Israel Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 144 Israel Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Information Procurement
  • Fig. 2 Primary Research Pattern
  • Fig. 3 Market Research Approaches
  • Fig. 4 Value Chain-Based Sizing & Forecasting
  • Fig. 5 Market Formulation & Validation
  • Fig. 6 Biomarker Testing Services, Market Segmentation
  • Fig. 7 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 8 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 9 Porter's Five Forces Analysis
  • Fig. 10 PESTEL Analysis
  • Fig. 11 Regional Marketplace: Key Takeaways
  • Fig. 12 Global Biomarker Testing Services, for Biomarker Assay Development & Validation, 2018 - 2030 (USD Million)
  • Fig. 13 Global Biomarker Testing Services: Service Key Takeaways
  • Fig. 14 Global Biomarker Testing Services: Service Movement Analysis
  • Fig. 15 Global Biomarker Testing Services, for Flow Cytometry, 2018 - 2030 (USD Million)
  • Fig. 16 Global Biomarker Testing Services, for Others, 2018 - 2030 (USD Million)
  • Fig. 17 Global Biomarker Testing Services: Application Key Takeaways
  • Fig. 18 Global Biomarker Testing Services: Application Movement Analysis
  • Fig. 19 Global Biomarker Testing Services, for Oncology, 2018 - 2030 (USD Million)
  • Fig. 20 Global Biomarker Testing Services, for Drug Discovery & Development, 2018 - 2030 (USD Million)
  • Fig. 21 Global Biomarker Testing Services, for Others, 2018 - 2030 (USD Million)
  • Fig. 22 Global Biomarker Testing Services: Type Key Takeaways
  • Fig. 23 Global Biomarker Testing Services: Type Movement Analysis
  • Fig. 24 Global Biomarker Testing Services, for Molecular Biomarkers, 2018 - 2030 (USD Million)
  • Fig. 25 Global Biomarker Testing Services, for Cellular Biomarkers, 2018 - 2030 (USD Million)
  • Fig. 26 Global Biomarker Testing Services: End Use Key Takeaways
  • Fig. 27 Global Biomarker Testing Services: End Use Movement Analysis
  • Fig. 28 Global Biomarker Testing Services, for Pharmaceutical and Biotechnology Companies, 2018-2030, (USD Million
  • Fig. 29 Global Biomarker Testing Services, for Research Institutes, 2018 - 2030 (USD Million)
  • Fig. 30 Global Biomarker Testing Services, for CROs, 2018 - 2030 (USD Million)
  • Fig. 31 Regional Outlook, 2024 & 2030
  • Fig. 32 North America Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 US Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Canada Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Mexico Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Europe Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Germany Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 UK Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 France Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Italy Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Spain Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Denmark Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Sweden Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Norway Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Asia Pacific Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Japan Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 China Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 India Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Australia Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 South Korea Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Thailand Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Indonesia Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Malaysia Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Singapore Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Taiwan Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Latin America Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Brazil Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Argentina Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Middle East and Africa Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 South Africa Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Saudi Arabia Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 UAE Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Kuwait Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Israel Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!